Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lü, Shun; Wang, Jie; Cheng, Ying; Mok, Tony; Chang, Jianhua; Zhang, Li; Feng, Jifeng; Tu, Hai‐Yan; Wu, Lin; Zhang, Yiping; Luft, Alexander; Zhou, Jianying; Ma, Zhiyong; Lu, You; Shi, Yuankai; Ying, Kejing; Poddubskaya, Elena; Soo, Ross A.; Chia, Yew Woon; Li, Ang; Li, Amy; Wu, Yi‐Long

doi:10.1016/j.lungcan.2020.11.013

Cited by 49 publications

(43 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 . Finally, 28 eligible articles reporting 24 RCTs (23 phase 3 and 1 phase 2 trials) with 13918 patients (11698 of smokers and 2220 of never smokers) were eligible for inclusion [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] . Because one studies [10] provided pooled OS data of CheckMate-017 [9] , and -057 [11] , the pooled data were used instead of data from the individual trials in this meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, never smokers should obtain less benefit from ICIs compared to smokers theoretically. However, this hypothesis has not been confirmed by current ICIs trials, in which inconsistent results were observed [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] . Some previous meta-analyses [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] have attempted to clarify the relationship between smoking and the efficacy of ICIs in NSCLC, while the lack of statistical power due to limitations such as small number of studies, small sample size, and few subgroup analysis prevents a final conclusion.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: It remains uncertain whether smoking status can effect efficacy of immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC). We performed a meta-analysis to address this issue.Patients and methods: PubMed, Embase, Cochrane Library, Web of Science, and international meetings were searched until April 1, 2021, for phase 2 and 3 randomized controlled trials (RCTs) which compared ICIs with chemotherapy (CT) and reported overall survival (OS) and/or progression-free survival (PFS) data according to smoking status. This meta-analysis was registered in INPLASY platform (#INPLASY202140025). The random-effect model was used for statistical analysis. Findings: Twenty-eight articles from 24 RCTs including 13918 patients were eligible. ICIs significantly prolonged OS than CT in smokers (hazard ratio [HR] = 0.75, 95% confidence interval [CI]: 0.69-0.81), but not in never-smokers (HR = 0.87, 95% CI: 0.74-1.04); while there was no significant treatment-smoking interaction (P interaction = 0.11). Significant heterogeneity was observed for both smokers (OS: I 2 = 60%, P = 0.0002; PFS: I 2 = 74%, P < 0.0001) and never smokers (PFS: I 2 = 69%, P < 0.0001). Subgroup analyses revealed that ICIs monotherapy significantly improved OS in smokers (HR = 0.76, 95% CI: 0.69-0.85) but not in never-smokers (HR = 0.93, 95% CI: 0.77-1.12, P interaction = 0.07), and treatment-smoking interaction was significant in patients with PD-L1 50% (HR, 0.61 vs 1.18; P interaction = 0.005). ICIs plus CT achieved better OS either in smokers or never-smokers (HR, 0.76 vs 0.61; P interaction = 0.39), while dual ICIs combination prolonged OS only in smokers but never-smokers (HR, 0.68 vs 1.02; P interaction = 0.02). Interpretation: Either ICIs monotherapy or combination therapy was superior to CT in smokers. While ICIs monotherapy and dual ICIs combination were less effective in never-smokers, and ICIs plus CT might be the optimal selection. Nevertheless, given the limitation of the high heterogeneity of studies included, the findings need to be confirmed by future RCTs focusing on this subject.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1 ). In total, 38 RCTs, including 41 studies with 20,173 patients with lung cancer, were included for quantitative analyses [ 6 – 8 , 14 – 48 ]. Eight studies explored the efficacy of ICI versus SOC in patients with SCLC (three studies on ipilimumab, two on atezolizumab, one on nivolumab, one about durvalumab, and one assessing tremelimumab plus durvalumab).…”

Section: Resultsmentioning

confidence: 99%

“…In patients with advanced NSCLC, anti-PD-1 monotherapy can achieve a median OS of 11.9 months, which was significantly superior to that with a SOC at 9.5 months (hazard ratio [HR]: 0.75; 95% confidence interval [CI]: 0.61–0.93). Furthermore, the incidence of treatment-related adverse events (TRAE) in the ICI group was reportedly lower than in the SOC group [ 8 ]. In patients with SCLC, anti-PD-L1 therapy as first-line treatment has demonstrated a better OS than platinum-etoposide treatment [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

Wang

Zhang

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background The advent of immune checkpoint inhibitors (ICIs) therapy has resulted in significant survival benefits in patients with non-small-cell lung cancer (NSCLC) without increasing toxicity. However, the utilisation of immunotherapy for small-cell lung cancer (SCLC) remains unclear, with a scarcity of systematic comparisons of therapeutic effects and safety of immunotherapy in these two major lung cancer subtypes. Herein, we aimed to provide a comprehensive landscape of immunotherapy and systematically review its specific efficacy and safety in advanced lung cancer, accounting for histological types. Methods We identified studies assessing immunotherapy for lung cancer with predefined endpoints, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAE), from PubMed, Embase, Medline, and Cochrane library. A random-effects or fixed-effect model was adopted according to different settings. Results Overall, 38 trials with 20,173 patients with lung cancer were included in this study. ICI therapy resulted in a significantly prolonged survival in both patients with NSCLC and SCLC when compared with chemotherapy (hazard ratio [HR] = 0.74; 95% confidence interval [CI], 0.70–0.79] and [HR = 0.82; 95% CI, 0.75–0.90], respectively). The magnitude of disease control and survival benefits appeared superior with ICI plus standard of care (SOC) when compared with SOC alone. OS and PFS advantages were observed only when immunotherapy was employed as the first-line treatment in patients with SCLC. Conclusion ICI therapy is a promising therapeutic option in patients with NSCLC and SCLC. ICI plus SOC can be recommended as the optimal first-line treatment for patients with SCLC, and double-target ICIs combined with SOC are recommended in patients with NSCLC as both the first and subsequent lines of treatment. Additionally, non-first-line immunotherapy is not recommended in patients with SCLC.

show abstract

“…In contrast, there was a decrease of just 4% in PET/CT scans ( 7 ). In a centre located in an area with a low prevalence of COVID-19, Maurea et al reported that the number of [ 18 F]FDG-PET/CT studies performed during the pandemic (n = 299) and in the corresponding period of 2019 (n = 335) were comparable (P = 0.74) ( 24 ). In NHS England PET-CT services, the turnaround time for [ 18 F]FDG PET-CT scans did not increase (indeed, the percentage of scans with a turnaround time of more than seven working days during April and May 2020 was lower than that in the same months in 2019).…”

Section: Impact On Diagnostic and Therapeutic Activitymentioning

confidence: 99%

The Impact of COVID-19 on Nuclear Medicine in Europe

Kirienko

Telo

Hustinx

et al. 2022

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

The COVID-19 pandemic has profoundly changed hospital activities, including nuclear medicine (NM) practice. This review aimed to determine and describe the impact of COVID-19 on NM in Europe and critically discuss actions and strategies applied to face the pandemic. A literature search for relevant articles was performed on PubMed, covering COVID-19 studies published up until January 21, 2021. The findings were summarized according to general and specific activities within the NM departments. The pandemic strongly challenged NM departments: a reduction in the workforce has been experienced in almost every centre in Europe due to personnel diagnosed with COVID-19 and other reasons related to the coronavirus. NM departments introduced procedures to limit COVID-19 transmission, including environmental and personal hygiene, social distancing, rescheduling of non–high-priority procedures, the correct use of personal protective equipment, and prompt identification of suspect COVID-19 cases. A proportion of the departments experienced a delay in radiopharmaceuticals supply or technical assistance during the pandemic. Furthermore, the pandemic resulted in a significant reduction of diagnostic and therapeutic NM procedures, as well as a reduced level of care for patients affected by diseases other than COVID-19, such as cancer or acute cardiovascular disease. Telemedicine services have been set up to maintain medical assistance for patients. COVID-19 pandemic has reshaped human work resources, patient's diagnostic and therapeutic management, operative models, radiopharmaceutical supplies, teaching, training and research of NM departments. Limits of availability of resources emerged. Nonetheless, we have to provide continuity in care, especially for fragile patients, maintaining infection control measures. Challenges that have been faced should reshape our vision and get us prepared for the future.

show abstract

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Cited by 49 publications

References 21 publications

The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis

The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

The Impact of COVID-19 on Nuclear Medicine in Europe

Contact Info

Product

Resources

About